Half-dose Pfizer COVID booster nearly as effective as full dose with fewer side effects

Study compares the half-dose and full-dose Pfizer-BioNTech BNT162b2 COVID-19 booster in adults previously vaccinated with ChAdOx1, BBIBP-CorV, or Gam-COVID-Vac. It finds that the half-dose booster has fewer side effects and maintains similar immunogenicity, offering a viable option for booster vaccination strategies.

Net Health Appoints Ron Books as CEO – Digital Health

Ron Books, CEO at Net Health What You Should Know: – Net Health, a trusted source for specialized software solutions that empower restorative care providers,

October 20, 2023

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

An anaplastic lymphoma kinase (ALK)-targeted agent induced high response rates for adults with ALK-positive anaplastic large cell lymphoma (ALCL) who had failed on brentuximab vedotin

June 13, 2024

Scientists discover a possible therapeutic target for pulmonary hypertension

A team led by Dr. Guadalupe Sabio at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid has discovered a possible therapeutic target for pulmonary

January 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.